Fundraising Fox
/Companies
Sign in

ENB Therapeutics

New York, US · Founded 2018 · Delaware corporation · 6 employees on LinkedIn · 4 known investors

Find your way into ENB Therapeutics

Sign up to see every warm intro you have to ENB Therapeutics

  • Paths you didn't know you had: your email and LinkedIn already hold routes to the ENB Therapeutics team. We find them for you
  • 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
  • Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone

Days of research, done the moment you sign in, with every route ranked by how warm it is.

Sign up with GoogleAlready have an account? Log in

ENB Therapeutics develops small molecules targeting the endothelin B receptor (ETBR) in the tumor microenvironment to treat drug-resistant cancers by restoring immune cell infiltration and promoting tertiary lymphoid organ formation. Its preclinical therapies target cancers including melanoma, glioblastoma, squamous cell carcinoma, bladder cancer, and ovarian cancer.

BiotechHealthtech

Founders & leadership

ENB Therapeutics was founded in 2018 by Sumayah Jamal and Robert Schneider.

SJ
Sumayah JamalPresident, Co-Founder, Chief Scientific OfficerSumayah Jamal is a dermatologist and biochemist with over 30 years of research experience, beginning her work on the endothelin axis in cancer as a postdoctoral fellow in 1997 and later serving as a professor at NYU School of Medicine. She is a co-inventor of patents covering the endothelin B receptor as a cancer therapeutic target and co-founded ENB Therapeutics in 2015, where she serves as President and Chief Scientific Officer.
RSRobert Schneider
Robert SchneiderCo-founder, Chair of Scientific Advisory Board
SH
Sandy HarmChief Operating OfficerSandy Harm holds advanced degrees in biology, health administration, and health care ethics with a focus on epidemiology and population health. As COO of ENB Therapeutics, Harm brings extensive experience in pharmaceutical R&D operations, clinical research, medical affairs, and project management across oncology and infectious diseases.
FM
Fumitaka MoriNamed on SEC filing
AS
Albert SokolNamed on SEC filing

Board

BSBarbara Schilberg
Barbara SchilbergBoard directorAdvisor & Former CEO at BioAdvance

Investors · 4

BioAdvancelisted by BioAdvanceConshohocken · $500K – $1.5M

How we know: BioAdvance's portfolio page · open dataset · 5k.vc investor directory · Not right? Tell us

Remiges Ventures, Inc.listed by Remiges Ventures, Inc.Seattle

How we know: Remiges Ventures, Inc.'s portfolio page · open dataset · 5k.vc investor directory · Not right? Tell us

Also in the syndicate · 1

ANY Seed Fund

Reported raises · per SEC filings

Form D private placements

$9.6M disclosed across 3 rounds · 2018–2023

▶$225KraisedOct 2023 · 3 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Sumayah JamalExecutive Officer, Director
  • Barbara SchilbergDirector
  • Stuart HwangDirector
  • Walter OlesiakDirector
  • Albert SokolExecutive Officer
Offering amount
$1M
Amount sold
$225K
First sale
Sep 2023
Incorporated
Corporation, Delaware, 2018
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$1.3MraisedJan 2021 · 3 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Barbara SchilbergDirector
  • Albert SokolExecutive Officer
  • Fumitaka MoriDirector
  • Sumayah JamalExecutive Officer, Director
Offering amount
$2.6M
Amount sold
$1.3M
First sale
Jan 2021
Incorporated
Corporation, Delaware, 2018
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$8.1MraisedFeb 2020 · 17 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Barbara SchilbergDirector
  • Fumitaka MoriDirector
  • Sumayah JamalExecutive Officer, Director
  • Albert SokolExecutive Officer
Offering amount
$9.1M
Amount sold
$8.1M
First sale
Sep 2018
Incorporated
Corporation, Delaware, 2018
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Related companies · 1

BioworldBioWorld is a suite of daily news and data services covering therapeutics, medical technology, biopharma business transactions, and drug R&D, serving biopharmaceutical and medtech industry professionals. Owned by Clarivate, it publishes products including BioWorld, BioWorld Science, and BioWorld Asia with reporting from writers stationed globally.

Companies working in the same space as ENB Therapeutics.

Frequently asked questions

What does ENB Therapeutics do?
ENB Therapeutics develops small molecules targeting the endothelin B receptor (ETBR) in the tumor microenvironment to treat drug-resistant cancers by restoring immune cell infiltration and promoting tertiary lymphoid organ formation. Its preclinical therapies target cancers including melanoma, glioblastoma, squamous cell carcinoma, bladder cancer, and ovarian cancer.
Who founded ENB Therapeutics?
ENB Therapeutics was founded by Sumayah Jamal, Robert Schneider in 2018.
Who are ENB Therapeutics's investors?
ENB Therapeutics's investors include Avestria Ventures, BioAdvance, Remiges Ventures, Inc..
How much funding has ENB Therapeutics raised?
ENB Therapeutics has disclosed $9.6M raised across 3 rounds.
Where is ENB Therapeutics headquartered?
ENB Therapeutics is headquartered in New York, US.